A61K 47/6839
The antibody targeting material from viruses
Official title: {the antibody targeting material from viruses}
A61K47/6839 (The antibody targeting material from viruses) appears on 134 US grants and 189 published applications in this corpus.
Search patents in A61K- Granted patents
- 134
- Published applications
- 189
- Assignees
- 122
- Inventors
- 408
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 3 |
| 2003 | 1 | 2 |
| 2004 | 1 | 5 |
| 2005 | 0 | 2 |
| 2006 | 3 | 4 |
| 2007 | 1 | 6 |
| 2008 | 0 | 3 |
| 2009 | 2 | 1 |
| 2010 | 2 | 7 |
| 2011 | 2 | 5 |
| 2012 | 2 | 4 |
| 2013 | 5 | 6 |
| 2014 | 9 | 10 |
| 2015 | 10 | 10 |
| 2016 | 8 | 16 |
| 2017 | 8 | 11 |
| 2018 | 7 | 10 |
| 2019 | 9 | 10 |
| 2020 | 9 | 13 |
| 2021 | 14 | 13 |
| 2022 | 4 | 7 |
| 2023 | 4 | 9 |
| 2024 | 7 | 16 |
| 2025 | 6 | 8 |
| 2026 | 4 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods of producing microbubble drug conjugates, viral gene therapy microbubble conjugates and targeted microbubbles29 Sep 2026US 12,746,292 B2
- Lassa virus-specific nanobodies and methods of their use29 Sep 2026US 12,747,284 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces10 Mar 2026US 12,570,763 B2The Board of Trustees of the Leland Stanford Junior University
- Protein-antiviral compound conjugates3 Mar 2026US 12,564,640 B2Regeneron Pharmaceuticals, Inc.
- Methods for manufacturing phthalocyanine dye conjugates and stable conjugates9 Dec 2025US 12,491,249 B2Rakuten Medical, Inc.
- Antibodies that bind to multiple sarbecoviruses17 Sep 2026US 2026/0274928 A1Vir Biotechnology, Inc.
- Novel Anti-HSV Antibody10 Sep 2026US 2026/0265348 A1Heidelberg ImmunoTherapeutics GmbH
- Nanobody for norovirus10 Sep 2026US 2026/0265349 A1Griffith University
- Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof10 Sep 2026US 2026/0266820 A1Icahn School of Medicine at Mount Sinai
- Protein-antiviral compound conjugates13 Aug 2026US 2026/0232822 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Immunoconjugates with an intracellularly-cleavable linkage85US 8,080,250 B1Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012
- Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme54US 5,718,915 ABurstein Laboratories, Inc. · 1998